WO2021215709A1 - Whitening cosmetic composition comprising sodium pyruvate as active ingredient - Google Patents

Abstract

The present invention relates to a whitening use of a composition that comprises: as active ingredients, sodium pyruvate, sodium pyruvate and hydroquinone, sodium pyruvate and arbutin, or sodium pyruvate, hydroquinone and arbutin. The whitening effect of sodium pyruvate was confirmed, and the disadvantages associated with skin safety, including apoptosis from hydroquinone and arbutin as compounds for skin whitening, can be overcome when applied together with sodium pyruvate, thereby providing an improved whitening effect. Therefore, the composition can be effectively used in cosmetics, medicines, external preparations, and the like.

Description

Whitening cosmetic composition containing sodium pyruvate as an active ingredient

The present invention relates to a cosmetic composition for whitening comprising sodium pyruvate as an active ingredient.

Skin color is determined by melanin, hemoglobin, carotene, etc. Among them, melanin plays the most important role. In addition to determining a person's skin color, melanin also performs skin protection functions such as UV absorption and free radical scavengers. However, when melanin is excessively generated by external environmental changes such as excessive exposure to ultraviolet rays, air pollution, stress, etc., it causes pigmentation in the skin, which causes skin blackening (melanism), blemishes, freckles, and the like. Blackening of the skin is caused by the reaction of skin cells to internal and external factors, and a representative factor is due to UV exposure. That is, when the skin is exposed to ultraviolet rays, tyrosinase is activated, and the tyrosinase acts on tyrosine present in the skin tissue to produce dopa (DOPA) and dopaquinone (dopaquinone) by an oxidation process, A polymer called melanin is synthesized from melanosomes in melanocytes, which are skin pigment cells, and this melanin is transferred to keratinocytes, which are keratinocytes of the skin, and reaches the skin surface through the keratinization process. It protects the skin from UV rays. However, when melanin is locally synthesized excessively or the physiological function of the skin is deteriorated due to skin lesions and aging, melanin is deposited on the skin surface, causing melasma, freckles and various pigmentation.

On the other hand, in human skin, melanocyte precursor cells (melanoblasts) are stored in the hair follicle epithelium, especially in the bulge (Nishimura et al, Science. 2005, 307(5710):720-4), and the epidermis between the hair follicles ( When melanocytes are removed from the basal layer of the interfollicular epidermis, melanocyte precursor cells migrate to this area, and at this time, not only UV rays but also adjacent cutaneous cells such as keratinocytes, fibroblasts or inflammatory cells Interaction between melanin synthesis (melanogenesis) and dendrite outgrowth required to move melanin granules to keratinocytes occurs and final differentiation occurs. Typically, a-melanocyte-stimulating hormone (MSH) is a melanocyte differentiation-promoting material secreted from UV-exposed keratinocytes. It promotes the proliferation of melanocyte precursor cells and the M promoter of microphtalmia-associated transcription factor (Mitf) in melanocytes. ), increases the expression of enzymes that cause pigment formation mechanisms such as tyrosinase, and causes melanosome formation and dendrite elongation. As such, the molecular mechanisms involved in the differentiation of melanocytes are precisely regulated.

As the cause and mechanism of skin blackening are revealed as described above, in the preparation of a whitening cosmetic or a pigmentation improvement medical composition, substances having an inhibitory effect on the activity of tyrosinase, an enzyme involved in the skin blackening process, are compounded, or melanin A method of reducing the production of melanin by inhibiting some reactions in the production process is generally used. Representative materials used for this purpose include chemical substances such as ascorbic acid, kojic acid, and hydroquinone, and plant extracts such as epiphyllum extract and licorice extract. However, ascorbic acid lacks tyrosinase activity inhibitory effect and is not suitable as a melanogenesis inhibitor due to low safety of the molecule itself, and kojic acid has excellent inhibitory activity of tyrosinase, Therefore, not only there is a problem in safety such as a decrease in potency, but there is a limitation in use due to large skin irritation, and hydroquinone is limited in use in cosmetics due to skin irritation and safety problems. restricted to contain.

Under this background, attention is focused on the development of effective whitening ingredients with excellent safety and safety.

In order to achieve the above object, as a result of intensive research efforts, there is a synergistic effect of inhibiting melanin production when sodium pyruvate and hydroquinone or arbutin, which are conventional tyrosinase activity inhibitory compounds, are combined at low concentrations, and apoptosis inhibition By confirming that even an effect is seen, this invention was completed.

It is an object of the present invention to provide a cosmetic composition for whitening that has an excellent melanin production inhibitory effect while not having problems with skin whitening efficacy and skin safety.

Another object of the present invention is a cosmetic composition for whitening comprising sodium pyruvate as an active ingredient; pharmaceutical compositions for the treatment of pigmentation; A composition for external application for skin for the treatment of pigmentation, and a whitening method using the composition, a method for treating pigmentation, and use for manufacturing a whitening cosmetic; and to provide a use for the manufacture of a therapeutic agent for pigmentation.

Another object of the present invention is sodium pyruvate and hydroquinone; sodium pyruvate and arbutin; Or a cosmetic composition for whitening comprising sodium pyruvate, hydroquinone and arbutin; pharmaceutical compositions for the treatment of pigmentation; Or a composition for external application to the skin for the treatment of pigmentation; And a whitening method using the composition, a method for treating hyperpigmentation, a use for manufacturing a whitening cosmetic; and to provide a use for the manufacture of a therapeutic agent for pigmentation.

In order to achieve the above object, there is provided a cosmetic composition for whitening comprising sodium pyruvate as an active ingredient.

In addition, it provides a cosmetic composition for whitening, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

The cosmetic composition in the present invention may be in the form of a lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.

In order to achieve the above object, there is provided a pharmaceutical composition for treating hyperpigmentation comprising sodium pyruvate as an active ingredient.

In addition, it provides a pharmaceutical composition for the treatment of pigmentation, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

In order to achieve the above object, there is provided a composition for external application for skin for the treatment of pigmentation comprising sodium pyruvate as an active ingredient.

In addition, it provides a composition for external application to the skin for the treatment of pigmentation, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

The composition for external application for skin in the present invention may be in the form of an ointment, patch, gel, cream or spray.

In order to achieve the above object, there is provided a whitening method comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.

In order to achieve the above object, there is provided a method for treating pigmentation, comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.

The composition may further include one or more selected from the group consisting of hydroquinone and arbutin.

In order to achieve the above object, there is provided the use of a composition comprising sodium pyruvate for preparing a whitening cosmetic.

In order to achieve the above object, there is provided the use of a composition comprising sodium pyruvate for the preparation of a therapeutic agent for pigmentation.

In order to achieve the above object, there is provided the use of a composition comprising sodium pyruvate for preparing an external preparation for the treatment of pigmentation.

The composition may further include one or more selected from the group consisting of hydroquinone and arbutin.

The cosmetic composition for whitening, the pharmaceutical composition for the treatment of pigmentation, and the composition for external application to the skin for the treatment of pigmentation of the present invention can overcome the disadvantages of safety and apoptosis, which are disadvantages of conventional tyrosinase activity inhibitory compounds.

sodium pyruvate; or sodium pyruvate and hydroquinone; or sodium pyruvate and arbutin; Alternatively, a composition comprising sodium pyruvate, hydroquinone, and arbutin as an active ingredient has the effect of inhibiting the differentiation of melanocytes, has the effect of inhibiting melanin synthesis, and reduces the apoptosis and skin safety problems of hydroquinone and arbutin with sodium pyruvate. It was confirmed that it was possible to overcome when used together. Accordingly, an improved whitening effect can be provided, and the composition of the present invention can be effectively used in cosmetics, medicines, external preparations, and the like.

1 is a result of the inhibitory effect of sodium pyruvate on dendrite elongation in B16F10 cells.

Hereinafter, the present invention will be described in detail.

In one aspect, the present invention provides a cosmetic composition for whitening comprising sodium pyruvate as an active ingredient.

In another aspect, it provides a cosmetic composition for whitening, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

In another aspect, there is provided a pharmaceutical composition for the treatment of pigmentation disorder comprising sodium pyruvate as an active ingredient.

In another aspect, it provides a pharmaceutical composition for the treatment of pigmentation, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

In another aspect, there is provided a composition for external application to the skin for the treatment of pigmentation comprising sodium pyruvate as an active ingredient.

In another aspect, there is provided a composition for external application for skin for the treatment of pigmentation, further comprising one or more selected from the group consisting of hydroquinone and arbutin.

In another aspect, a whitening method using a composition comprising sodium pyruvate as an active ingredient, a method for treating pigmentation, use for preparing a whitening cosmetic; and for the manufacture of a therapeutic agent for pigmentation.

In another aspect, sodium pyruvate and hydroquinone; sodium pyruvate and arbutin; or a whitening method using a composition comprising sodium pyruvate, hydroquinone, and arbutin, a method for treating pigmentation disorders, and use for preparing a whitening cosmetic; and for the manufacture of a therapeutic agent for pigmentation.

In another aspect, there is provided a whitening method comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.

In another aspect, there is provided a method for treating pigmentation, comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.

The composition may further include one or more selected from the group consisting of hydroquinone and arbutin.

In another aspect, there is provided the use of a composition comprising sodium pyruvate for preparing a whitening cosmetic.

In another aspect, there is provided the use of a composition comprising sodium pyruvate for the manufacture of a therapeutic agent for pigmentation.

In another aspect, there is provided the use of a composition comprising sodium pyruvate for preparing an external preparation for the treatment of pigmentation.

The composition may further include one or more selected from the group consisting of hydroquinone and arbutin.

"Sodium pyruvate" of the present invention is represented by the following [Formula 1] and is another salt form of pyruvic acid, which is one of a-keto acids.

[Formula 1]

Because pyruvate is an intermediate in many metabolic pathways, sodium pyruvate is widely used to provide more energy in many experiments involving cell culture. According to previous studies, pyruvic acid not only suppresses melasma, solar lentigine, acne, and warts, but also promotes collagen synthesis and improves skin elasticity. (50~100%), since it is an effect due to chemical exfoliation, you may feel a stinging or burning sensation while using pyruvic acid, and excessive exfoliation of dead skin cells or inflammatory blisters may be accompanied. The human efficacy at low concentrations in which chemical exfoliation does not occur is unknown. According to the results of a recent study, it was confirmed through an in vitro experiment that when 0.055% pyruvic acid was treated in cells, it had the effect of inhibiting melanin synthesis, but it was reported that sodium pyruvate had no effect on inhibiting melanin synthesis.

"Hydroquinone (HQ)" of the present invention is represented by [Formula 2], also known as benzene-1,4-diol or quinol. It is an aromatic organic compound that is a type of phenol.

[Formula 2]

Hydroquinone is used for topical application for skin whitening, but its use is limited because it can irritate the skin when used in high concentrations.

"Arbutin" of the present invention is represented by [Formula 3]. As a type of glucoside, it is a glycosylated hydroquinone extracted from bearberry of the genus Arctostaphylos of the Azalea family.

[Formula 3]

Arbutin is used for skin whitening treatment, but like hydroquinone, arbutin can irritate the skin when used in high concentrations, so special attention is required.

In the present invention, when hydroquinone and arbutin are applied to the skin, safety problems such as cytotoxicity or skin cell death, which are problematic, are overcome by applying together with sodium pyruvate. In particular, when sodium pyruvate and hydroquinone and/or arbutin are used together, it is possible to provide sufficient melanin synthesis inhibitory effect even at a low concentration due to the synergistic effect between the components.

The "skin whitening effect" of the present invention not only brightens the skin tone by inhibiting the synthesis of melanin pigment and the differentiation of melanocytes, but also makes the skin tone or complexion uniform, UV rays, hormonal or genetic blemishes, hyperpigmentation after inflammation It refers to, but is not limited to, improving pigmentation, changes in pigmentation due to skin aging, age spots or brown spots, freckles, and hyperpigmentation.

When the sodium pyruvate, sodium pyruvate and hydroquinone or sodium pyruvate and arbutin are used as cosmetics, cosmetics prepared by containing the compounds and mixtures as active ingredients can be prepared in the form of general emulsified formulations or solubilized formulations. have. For example, a lotion such as a softening lotion or a nourishing lotion; Emulsion such as facial lotion or body lotion, cream such as nourishing cream, moisture cream or eye cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, liquid type, solid type or spray type foundation; Powders, cleansing creams, cleansing lotions, make-up removers such as cleansing oils, cleansing foams, soaps, body washes, and the like may have formulations.

In addition, the composition of the present invention comprises a fatty substance, an organic solvent, a solubilizer, a thickening agent, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic emulsifier, a nonionic Additional additives commonly used in the cosmetic field, such as emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic active agents, lipophilic active agents or lipid vesicles may contain.

The composition may include sodium pyruvate in an amount of 0.001 to 5% (w/w) based on the total weight of the composition. When the composition of the present invention contains less than 0.001% (w/w) of sodium pyruvate, a sufficient skin whitening effect cannot be expected.

The sodium pyruvate is preferably 0.005 to 4% (w/w), more preferably 0.01 to 2% (w/w), and most preferably 0.05 to 1% (w/w) based on the total weight of the composition. can be included as

The composition may include hydroquinone in an amount of 0.001 to 6% (w/w) based on the total weight of the composition. When the composition of the present invention contains less than 0.001% (w/w) of hydroquinone, a sufficient skin whitening effect cannot be expected, and when it contains more than 6% (w/w), unwanted reactions such as allergies may occur. It may occur or there may be problems with skin safety.

The hydroquinone is 0.005 to 6% (w / w), 0.01 to 5% (w / w), 0.05 to 4% (w / w), or 0.1 to 2% (w / w) based on the total weight of the composition. may include

The composition may include arbutin in an amount of 0.001 to 10% (w/w) based on the total weight of the composition. When the composition of the present invention contains less than 0.001% (w/w) of arbutin, a sufficient skin whitening effect cannot be expected, and when it contains more than 5% (w/w), unwanted reactions such as allergies occur. Or there may be a problem with skin safety.

The arbutin is included in 0.005 to 10% (w/w), 0.01 to 6% (w/w), 0.05 to 5% (w/w), or 0.1 to 2% (w/w) by weight of the total composition can do.

The composition includes active ingredients sodium pyruvate and hydroquinone; or sodium pyruvate and arbutin; Or sodium pyruvate, hydroquinone and arbutin based on the total weight of the composition 0.002 to 10% (w / w), 0.005 to 6% (w / w), 0.01 to 5% (w / w), 0.05 to 4% ( w/w), or 0.1 to 3% (w/w). When the active ingredient of the present invention is included in less than 0.002% (w/w), a sufficient skin whitening effect cannot be expected, and when it contains more than 10% (w/w), unwanted reactions such as allergies occur. Or there may be a problem with skin safety.

The 'pharmaceutical composition' of the present invention can be administered orally or parenterally, and when sodium pyruvate, sodium pyruvate and hydroquinone or sodium pyruvate and arbutin are used as pharmaceutical compositions, the form of a generic pharmaceutical preparation, For example, it can be administered in various oral and parenteral dosage forms during clinical administration. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. can, but is not limited thereto.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the pharmaceutical composition of the present invention, for example, starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin, etc., but is not limited thereto.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included. not limited

The 'composition for external application to the skin' of the present invention may be used as an external preparation for skin, but is not limited thereto. When sodium pyruvate, sodium pyruvate and hydroquinone, and sodium pyruvate and arbutin are used as external preparations for skin, fat substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, and stabilizing agents are additionally used. Agents, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilicity Or it may contain adjuvants commonly used in the field of dermatology, such as lipophilic active agents, lipid vesicles, or any other ingredients commonly used in external preparations for skin. In addition, the ingredients may be introduced in an amount generally used in the field of dermatology. When provided as an external preparation for skin, it may have a formulation such as, but not limited to, an ointment, a patch, a gel, a cream, or a spray.

Each of the above-mentioned components included in the composition according to the present invention may preferably be included in the composition of the present invention within a range not exceeding the maximum amount specified in the norms stipulated by the respective national governments. For example, in the case of providing a pharmaceutical composition, it may be included in the present invention within the scope of the manufacturing method, properties, amount of use, etc. specified in the Pharmacopoeia or drug collection prescribed in Korea, the United States, Europe, Germany, Japan, China, etc. . In addition, in the case of providing a cosmetic composition, the cosmetic composition of the present invention may be included in the cosmetic composition of the present invention to the extent that it does not exceed the maximum amount specified in the Cosmetic Safety Act stipulated by each country or the “Cosmetic Safety Technical Specification” stipulated by the Chinese government. can

Hereinafter, the present invention will be described in detail by the following experimental examples. However, the following experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following experimental examples. In addition, since these experimental examples are only for the purpose of helping the understanding of the present invention, the scope of the present invention is not limited thereto in any sense.

Experimental Example 1: Confirmation of inhibition of melanocyte differentiation by sodium pyruvate

In order to check whether the dendrite elongation of melanocytes is inhibited by sodium pyruvate, B16F10 cells (ATCC, catalog number CRL-6475) were first ^{aliquoted in a 6-well plate at a concentration of 1 x 10 5} cells/well and cultured for 24 hours. . To create a model for promoting melanin synthesis, 10 nM of α-MSH (α-Melanocytes Stimulating Hormone) was treated in the control cells after culture, and the experimental group was treated with 10 nM of α-MSH and 10 mM sodium pyruvate in the cells. After 48 hours in both control and experimental groups, the length of dendrites was measured under a microscope (EVOS FL auto 2, Termo Fisher Scientific).

additive compound	Length of dendrites (μm)
sodium pyruvate	25.7 ± 16.5
Control group (α-MSH treatment group)	69.8 ± 29.5

As a result, as shown in Table 1 and Figure 1, in the control group, dendrites were elongated to an average of 69.8 μm by the differentiation factor, but in the group treated with sodium pyruvate, the elongation was inhibited to an average of 25.6 μm. it can be seen that It can be seen that the sodium pyruvate of the present invention can inhibit melanin synthesis and secretion by inhibiting melanocyte dendrite elongation.

Experimental Example 2: Synergistic effect of sodium pyruvate and hydroquinone

B16F10 cells were aliquoted in a 96-well plate at a ^{concentration of 2 x 10 3} cells/well and cultured in DMEM medium containing 10% FBS and 1% penicillin/streptomycin for 24 hours at 37°C and 5% CO _{2 condition.} As shown in Table 2, sodium pyruvate or hydroquinone (HQ) was treated for 48 hours at each concentration, and then cytotoxicity was tested by CCK-8 assay, and the results are shown in Table 2. The negative control group was a condition in which neither sodium pyruvate nor HQ was treated, and the cell viability of the experimental group treated with sodium pyruvate or hydroquinone (HQ) was calculated as a percentage compared to the negative control group, and is shown in Table 2.

To measure melanin content, first, B16F10 cells were dispensed in a 6-well ^{plate at a concentration of 1 x 10 5} cells/well, and DMEM medium containing 10% FBS and 1% penicillin/streptomycin for 24 hours at _{37°C and 5% CO 2 conditions.} cultured in Then, the cells were treated with α-MSH 10 nM and sodium pyruvate or hydroquinone (HQ) at different concentrations as shown in Table 3 for 48 hours. After harvesting the cells, 100 μl of lysis buffer (lysis buffer, 1N NaOH, 10% DMSO) was added and reacted at 90° C. for 20 minutes, and then the amount of melanin was measured at 405 nm (EPOCH, Biotek). Table 3 shows the relative amount (%) of melanin compared to the negative control group as a negative control when sodium pyruvate and HQ were not treated.

The inhibition rate (%) of melanin production in Table 3 was calculated by subtracting the amount of melanin production (%) from the negative control group (100) compared to the negative control group, and was calculated according to Equation 1 below.

Formula 1: [(Negative control group melanin synthesis amount - experimental group melanin synthesis amount) / negative control group melanin synthesis amount] x 100

sample name	Sodium Pyruvate Concentration (ppm)	Hydroquinone (HQ) concentration (ppm)	Cell viability (%) compared to negative control
negative control	-	-	100
Example 1	50	-	104.9
Comparative Example 1	-	2.5	87.3
Example 2	100	-	110.5
Comparative Example 2	-	5	59.8
Example 3	50	2.5	92
Example 4	100	2.5	97.1

As shown in Table 2, cell viability showed cytotoxicity of 12.7% and 40.2% when treated with HQ 2.5ppm alone (Comparative Example 1) and 40.2% when treated with HQ 2.5ppm (Comparative Example 2), but with HQ 2.5ppm and sodium pyruvate. When treated with 50 ppm and 100 ppm (Examples 3 and 4), the cytotoxicity was reduced to 8% and 2.9%.

sample name	Sodium Pyruvate Concentration (ppm)	Hydroquinone (HQ) concentration (ppm)	Amount of melanin production compared to negative control (%)	Melanin production inhibition rate (%)
negative control	-	-	100	0
Example 1	50	-	74.4	25.6
Comparative Example 1	-	2.5	42.7	53.7
Example 2	100	-	65	35
Comparative Example 2	-	5	32.9	67.1
Example 3	50	2.5	16.4	83.6
Example 4	100	2.5	4.3	95.7

In Table 3, the melanogenesis inhibition rate of HQ also increased from 53.7% when treated with HQ 2.5 ppm alone (Comparative Example 1) to 83.6% and 95.7% when treated with sodium pyruvate 50ppm and 100ppm (Examples 3 and 4), respectively. did. This is a higher efficacy than 67.1% when HQ 5ppm (Comparative Example 2) is treated alone, and it can be confirmed that there is a melanin production inhibitory effect as a very high synergistic effect because the cytotoxicity is also significantly lower. Accordingly, the composition according to one aspect of the present invention will exhibit remarkable skin whitening, melanogenesis inhibition or pigmentation inhibition effects.

Experimental Example 3: Synergistic effect of sodium pyruvate and arbutin

The melanin content was measured by combining the cell viability and melanogenesis inhibition rate of sodium pyruvate and arbutin, which is a sugar derivative of hydroquinone, according to the same experimental method as in Experimental Example 2. The inhibition rate (%) of melanin production in Table 5 is a value obtained by subtracting the amount of melanin production (%) from the negative control group (100) compared to the negative control group, and was calculated according to Equation 1 below.

Formula 1: [(Negative control group melanin synthesis amount - experimental group melanin synthesis amount) / negative control group melanin synthesis amount] x 100

sample name	Sodium Pyruvate Concentration (ppm)	Arbutin Concentration (ppm)	Cell viability (%) compared to negative control
negative control	-	-	100
Example 1	50	-	104.9
Comparative Example 3	-	50	98.2
Example 2	100	-	110.5
Comparative Example 4	-	100	87.9
Example 5	20	80	95
Example 6	50	50	98.7
Example 7	80	20	99.4

sample name	Sodium Pyruvate Concentration (ppm)	Arbutin Concentration (ppm)	Amount of melanin production compared to negative control (%)	Melanin production inhibition rate (%)
negative control	-	-	100	0
Example 1	50	-	74.4	25.6
Comparative Example 3	-	50	80.6	19.4
Example 2	100	-	65	35
Comparative Example 4	-	100	72.4	27.6
Example 5	20	80	68.3	31.7
Example 6	50	50	42.6	57.4
Example 7	80	20	55.1	44.9

According to Table 4, 100ppm of sodium pyruvate and arbutin in B16F10 cells compared to the control showed cell viability of 110.5% (Example 2) and 87.9% (Comparative Example 4), respectively. At this time, in the case of the combined treatment of sodium pyruvate and arbutin, when the weight ratio is 2:8, 95% (Example 5), 5:5, 98.7% (Example 6), and 8:2, 99.4% ( Example 7) showed the cell viability. In addition, as can be seen in Table 5, 100 ppm of sodium pyruvate and arbutin compared to the control showed melanin production inhibition efficiency of 35% (Example 2) and 27.6% (Comparative Example 4), respectively, and the combination of sodium pyruvate and arbutin In the case of treatment, the weight ratio of 31.7% (Example 5) of 2:8, 57.4% (Example 6) of 5:5, and 44.9% (Example 7) of 44.9% (Example 7) when the weight ratio is seemed These results show that when the two substances are treated together, it can be seen that a more remarkably good effect is exhibited, and in particular, the melanin production inhibitory effect is the most excellent in the case of a weight ratio of 5:5 even in the combined treatment.

Claims (17)

1. A cosmetic composition for whitening comprising sodium pyruvate as an active ingredient.
2. The method of claim 1,

   The composition further comprises one or more selected from the group consisting of hydroquinone and arbutin, cosmetic composition for whitening.
3. The method of claim 1,

   The cosmetic composition for whitening is the formulation of a lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.
4. A pharmaceutical composition for treating hyperpigmentation comprising sodium pyruvate as an active ingredient.
5. 5. The method of claim 4,

   The composition further comprises one or more selected from the group consisting of hydroquinone and arbutin, a pharmaceutical composition for the treatment of pigmentation.
6. 5. The method of claim 4,

   Pigmentation is at least one selected from the group consisting of melasma, hyperpigmentation after inflammation, pigmentation due to skin aging, age spots, brown spots, freckles, and hyperpigmentation, a pharmaceutical composition for treating pigmentation.
7. A composition for external application for the treatment of pigmentation comprising sodium pyruvate as an active ingredient.
8. 8. The method of claim 7,

   The composition further comprises one or more selected from the group consisting of hydroquinone and arbutin.
9. 8. The method of claim 7,

   The external application is an ointment, a patch, a gel, a cream or a spray formulation for the treatment of pigmentation external application for the skin.
10. 8. The method of claim 7,

    Pigmentation is at least one selected from the group consisting of melasma, hyperpigmentation after inflammation, pigmentation due to skin aging, age spots, brown spots, freckles, and hyperpigmentation, a composition for external application for the treatment of pigmentation.
11. A whitening method comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.
12. A method for treating pigmentation, comprising the step of treating the skin with a composition comprising sodium pyruvate as an active ingredient.
13. The method according to any one of claims 11 to 12, wherein the composition further comprises at least one selected from the group consisting of hydroquinone and arbutin.
14. Use of a composition comprising sodium pyruvate for the manufacture of a whitening cosmetic.
15. Use of a composition comprising sodium pyruvate for the manufacture of a treatment for pigmentation.
16. Use of a composition comprising sodium pyruvate for preparing an external preparation for the treatment of pigmentation disorders.
17. 17. The use according to any one of claims 14 to 16, wherein the composition further comprises at least one selected from the group consisting of hydroquinone and arbutin.

Images